Akebia Therapeutics (NASDAQ:AKBA) will release its quarterly earnings report on Monday, 2025-11-10. Here’s a brief overview for investors ahead of the announcement.
Analysts anticipate Akebia Therapeutics to report an earnings per share (EPS) of $-0.02.
The market awaits Akebia Therapeutics’s announcement, with hopes high for news of surpassing estimates and providing upbeat guidance for the next quarter.
It’s important for new investors to understand that guidance can be a significant driver of stock prices.
Overview of Past Earnings
The company’s EPS beat by $0.02 in the last quarter, leading to a 13.62% increase in the share price on the following day.
Here’s a look at Akebia Therapeutics’s past performance and the resulting price change:
Quarter
Q2 2025
Q1 2025
Q4 2024
Q3 2024
EPS Estimate
-0.02
-0.04
-0.08
-0.06
EPS Actual
0.00
0.03
-0.10
-0.10
Price Change %
14.00
-3.00
34.00
4.00
Market Performance of Akebia Therapeutics’s Stock
Shares of Akebia Therapeutics were trading at $2.01 as of November 06. Over the last 52-week period, shares are up 1.26%. Given that these returns are generally positive, long-term shareholders are likely bullish going into this earnings release.
Analysts’ Take on Akebia Therapeutics
Understanding market sentiments and expectations within the industry is crucial for investors. This analysis delves into the latest insights on Akebia Therapeutics.
The consensus rating for Akebia Therapeutics is Buy, …
Leave a Reply
You must be logged in to post a comment.